KMT2A and leukemia: As DOT1L emerged as an essential molecular drug target in acute leukemias harboring a KMT2A-fusion protein, small-molecule inhibitors targeting DOT1L were developed to reverse aberrantly expressed leukemic transcriptional programs in those leukemias.